TY  - JOUR
A1  - Esnault, Clara
A1  - Schrama, David
A1  - Houben, Roland
A1  - Guyétant, Serge
A1  - Desgranges, Audrey
A1  - Martin, Camille
A1  - Berthon, Patricia
A1  - Viaud-Massuard, Marie-Claude
A1  - Touzé, Antoine
A1  - Kervarrec, Thibault
A1  - Samimi, Mahtab
T1  - Antibody–drug conjugates as an emerging therapy in oncodermatology
JF  - Cancers
N2  - Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
KW  - antibody–drug conjugates
KW  - oncodermatology
KW  - melanoma
KW  - skin squamous cell carcinoma
KW  - cutaneous T-cell lymphoma and Merkel cell carcinoma
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262192
SN  - 2072-6694
VL  - 14
IS  - 3
ER  - 
TY  - JOUR
A1  - Kervarrec, Thibault
A1  - Samimi, Mahtab
A1  - Guyétant, Serge
A1  - Sarma, Bhavishya
A1  - Chéret, Jérémy
A1  - Blanchard, Emmanuelle
A1  - Berthon, Patricia
A1  - Schrama, David
A1  - Houben, Roland
A1  - Touzé, Antoine
T1  - Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review
JF  - Frontiers in Oncology
N2  - Merkel cell carcinoma (MCC) is a primary neuroendocrine carcinoma of the skin. This neoplasia features aggressive behavior, resulting in a 5-year overall survival rate of 40%. In 2008, Feng et al. identified Merkel cell polyomavirus (MCPyV) integration into the host genome as the main event leading to MCC oncogenesis. However, despite identification of this crucial viral oncogenic trigger, the nature of the cell in which MCC oncogenesis occurs is actually unknown. In fact, several hypotheses have been proposed. Despite the large similarity in phenotype features between MCC tumor cells and physiological Merkel cells (MCs), a specialized subpopulation of the epidermis acting as mechanoreceptor of the skin, several points argue against the hypothesis that MCC derives directly from MCs. Alternatively, MCPyV integration could occur in another cell type and induce acquisition of an MC-like phenotype. Accordingly, an epithelial as well as a fibroblastic or B-cell origin of MCC has been proposed mainly based on phenotype similarities shared by MCC and these potential ancestries. The aim of this present review is to provide a comprehensive review of the current knowledge of the histogenesis of MCC.
KW  - merkel cell polyomavirus (MCPyV)
KW  - epithelial
KW  - fibroblast
KW  - B cell
KW  - Merkel cell carcinoma (MCC)
KW  - histogenesis
KW  - origin
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325733
VL  - 9
ER  -